Last updated: July 31, 2026
Crotamiton is an established topical antipruritic and scabicide marketed primarily as a 10% cream or lotion. Its clinical-development profile is mature, with no visible late-stage innovation program and limited current trial activity. Commercial demand is concentrated in generic and branded topical products for scabies and pruritus. The product has low patent risk, no meaningful biologic or biosimilar exposure, and limited prospects for material market expansion without a new formulation, delivery system, or differentiated clinical indication.
What is crotamiton and how is it used?
Crotamiton is a synthetic acaricide and antipruritic used topically for scabies and itching associated with dermatologic conditions. The drug is available in 10% topical formulations, including cream and lotion products.
| Attribute |
Crotamiton profile |
| Active ingredient |
Crotamiton |
| Common strength |
10% |
| Dosage forms |
Cream, lotion |
| Main indications |
Scabies; pruritus |
| Administration |
Topical |
| Drug class |
Acaricide; antipruritic |
| Common brand |
Eurax |
| Primary competitors |
Permethrin, ivermectin, sulfur preparations, benzyl benzoate |
| Regulatory maturity |
Long-established product |
| Biosimilar exposure |
None |
| Patent risk |
Low for the active ingredient and legacy formulations |
Crotamiton is generally applied to affected skin under product-specific instructions. Treatment instructions differ by label and jurisdiction. Patients and clinicians must follow the applicable product labeling because dosing, duration, age restrictions, and application requirements can vary between cream and lotion products.
The drug has a narrower role in scabies treatment than permethrin and oral ivermectin. The Centers for Disease Control and Prevention lists permethrin cream and ivermectin among the principal treatment options for scabies, while crotamiton is generally used as an alternative topical therapy rather than the dominant first-line product (Centers for Disease Control and Prevention, 2024).
What clinical trials have evaluated crotamiton?
Crotamiton has a limited modern clinical-trial pipeline. Most evidence comes from older controlled studies, post-market experience, dermatology practice, and comparative evaluations of scabies or pruritus treatments rather than contemporary registration trials.
Current clinical-trial status
Public trial registries do not show a substantial active development program for crotamiton as a novel therapy. There is no well-established Phase 2 or Phase 3 pipeline directed toward a new crotamiton indication, long-acting delivery system, or combination product.
The absence of an active late-stage pipeline reflects the drug’s age and generic market position. Companies selling crotamiton generally compete through manufacturing, distribution, price, formulation quality, and availability rather than through new clinical development.
Clinical evidence in scabies
Crotamiton has been studied as a topical scabicide, but its comparative position is weaker than permethrin in many modern treatment guidelines. Treatment outcomes can depend on application technique, adherence, reinfestation control, household treatment, disease severity, and local resistance patterns affecting competing therapies.
Crotamiton may remain commercially relevant where:
- Permethrin is unavailable or unsuitable.
- Patients require a non-oral topical option.
- Local formularies include crotamiton.
- Physicians use it for pruritus after scabies treatment.
- Pharmacies supply the product through legacy demand.
Clinical evidence does not support a broad claim that crotamiton has displaced permethrin or ivermectin in routine scabies management.
Clinical evidence in pruritus
Crotamiton is used as a topical antipruritic, but its evidence base is less differentiated than newer topical agents used for specific inflammatory or neuropathic itch conditions. It does not have a leading position in modern development programs targeting atopic dermatitis, prurigo nodularis, chronic kidney disease-associated pruritus, or cholestatic itch.
No major current clinical program is centered on crotamiton for these high-value indications.
What is the FDA regulatory status of crotamiton?
Crotamiton has a long-established U.S. regulatory history, but its precise marketing status depends on the individual product and manufacturer. U.S. products have been marketed as prescription topical products, while other jurisdictions may classify products differently.
The FDA-approved labeling for Eurax identifies crotamiton cream as a topical treatment for scabies and pruritus (DailyMed, 2024). Product-level status should be verified through FDA Drugs@FDA, the current DailyMed label, and the manufacturer’s National Drug Code listing because marketing authorizations and label availability can change.
FDA regulatory considerations
| Regulatory issue |
Assessment |
| New drug development |
No visible active innovative program |
| Generic competition |
Established or likely, depending on jurisdiction and product |
| OTC status |
Product-specific; not uniform across markets |
| Prescription status |
Applies to certain U.S. products |
| Pediatric labeling |
Must be assessed by product label |
| Safety monitoring |
Routine post-market pharmacovigilance |
| Combination-product opportunity |
Possible, but would require regulatory and clinical support |
The FDA’s regulatory pathway for a new crotamiton product would depend on whether the sponsor pursued an abbreviated application, a reformulated product, an OTC pathway, or a new drug application. A materially different indication or delivery system would require supporting clinical and chemistry, manufacturing, and controls data.
What patents protect crotamiton products?
The core crotamiton molecule is an old small-molecule active ingredient. Its fundamental composition-of-matter protection is no longer commercially relevant. Legacy patents covering the active ingredient, basic topical use, or early formulations would have expired long ago.
Patent estate assessment
| Patent category |
Current risk assessment |
| Composition of matter |
Expired |
| Basic scabies use |
Expired or commercially weak |
| Basic antipruritic use |
Expired or commercially weak |
| Conventional 10% cream |
Low risk |
| Conventional lotion |
Low risk |
| New vehicle or delivery system |
Potentially protectable if novel |
| Combination formulation |
Potentially protectable |
| Manufacturing process |
Potentially protectable if non-obvious |
| Patent term extension |
No meaningful current relevance |
Crotamiton does not have the type of active patent estate associated with a recently approved branded drug. Any remaining rights would more likely involve a specific formulation, manufacturing process, packaging system, or combination product rather than the active ingredient itself.
What is the Orange Book status of crotamiton?
Crotamiton’s Orange Book relevance is limited compared with major branded prescription products. The principal commercial issue is whether a specific marketed product has a current FDA approval listed in the Orange Book and whether that product carries any unexpired patents or regulatory exclusivity.
No material, widely recognized Orange Book patent barrier is associated with the conventional crotamiton 10% products used for scabies and pruritus. A product-specific Orange Book review remains necessary for litigation or abbreviated new drug application strategy because listing status can differ by sponsor and application.
When does crotamiton lose exclusivity?
Crotamiton’s active-ingredient exclusivity was lost decades ago. There is no commercially meaningful remaining exclusivity period for the legacy molecule or conventional topical use.
| Exclusivity category |
Expected status |
| Active-ingredient patent |
Expired |
| Original formulation exclusivity |
Expired |
| Pediatric exclusivity |
No current commercial relevance |
| Orphan exclusivity |
Not applicable to the legacy product |
| New chemical entity exclusivity |
Expired |
| Current formulation exclusivity |
Product-specific, if any |
| Market exclusivity |
Primarily based on branding and distribution |
The commercial entry risk for a conventional generic crotamiton cream or lotion is therefore driven by regulatory approval, manufacturing economics, supply availability, and pharmacy access rather than patent expiration timing.
Are there Paragraph IV challenges involving crotamiton?
No major, commercially consequential Paragraph IV campaign involving crotamiton is widely identified in the public pharmaceutical litigation landscape. The product’s age, low market value, and limited branded revenue reduce the incentive for patent litigation.
A Paragraph IV filing would generally be relevant only if a sponsor held an approved product with listed patents covering a specific formulation or delivery system. For standard crotamiton 10% products, the practical generic-entry barrier is low.
What patent litigation affects crotamiton?
There is no prominent current U.S. patent litigation campaign comparable to disputes involving high-revenue dermatology products, biologics, or specialty drugs. Litigation risk is more likely to arise from:
- Trademark disputes involving brand names.
- Labeling or promotional claims.
- Product liability matters.
- Manufacturing or supply agreements.
- Formulation patents for a newly developed product.
- Regulatory disputes involving application approval.
The absence of high-value patent litigation reflects the low economic value of the legacy product rather than a strong modern patent position.
What formulations are protected by crotamiton patents?
Conventional 10% cream and lotion formulations are unlikely to provide meaningful standalone patent protection today. A sponsor seeking new exclusivity would need to develop a formulation with measurable technical or clinical differentiation.
Potential patentable areas include:
- Enhanced skin penetration: A vehicle designed to improve delivery into the stratum corneum while reducing systemic exposure.
- Reduced irritation: A formulation that lowers burning, erythema, or contact dermatitis.
- Extended residence time: A cream, gel, foam, film, or emulsion that reduces reapplication.
- Combination therapy: Crotamiton combined with another scabicide, anti-inflammatory, keratolytic, or antipruritic.
- Pediatric delivery: A stable and acceptable formulation designed for children, subject to clinical and regulatory requirements.
- Improved packaging: Single-use or unit-dose packaging designed to improve adherence and reduce household transmission.
- Manufacturing process: A process that improves particle size, stability, purity, or product uniformity.
A formulation patent would face obviousness and enablement challenges if it merely substituted a conventional excipient or reproduced known topical technology without a demonstrated technical benefit.
Which companies are challenging or competing with crotamiton?
Crotamiton competes with both prescription and nonprescription scabies and antipruritic products. The most important competitive products include permethrin 5% cream and oral ivermectin. Sulfur ointments, benzyl benzoate, malathion in some markets, and newer antipruritic products also compete for specific patient segments.
| Competitor |
Typical role |
Competitive advantage |
| Permethrin 5% |
Common first-line scabies treatment |
Guideline support and broad availability |
| Oral ivermectin |
Systemic scabies treatment |
Convenience for extensive or outbreak-associated disease |
| Sulfur preparations |
Alternative scabies treatment |
Low cost and long clinical history |
| Benzyl benzoate |
Regional scabies treatment |
Availability in selected markets |
| Crotamiton |
Alternative topical therapy and antipruritic |
Established use and topical administration |
| Newer antipruritics |
Condition-specific itch treatment |
Stronger differentiation for defined diseases |
The main competitive threat is not a patented replacement for crotamiton. It is therapeutic substitution by permethrin, ivermectin, and condition-specific treatments.
How strong is the crotamiton patent estate?
The legacy patent estate is weak for commercial defense. Crotamiton has four characteristics that reduce exclusivity strength:
- The active ingredient is old.
- Conventional topical formulations are technically mature.
- Generic substitution is feasible.
- Clinical differentiation is limited.
Patent strength could improve only through a new product with evidence of a meaningful advantage, such as improved adherence, reduced toxicity, shorter treatment duration, or better efficacy in a defined patient population.
A new patent portfolio would need claims covering several layers:
| Protection layer |
Strategic value |
| Composition or salt form |
High if genuinely novel, but difficult for an old molecule |
| Formulation |
Moderate to high if technically differentiated |
| Method of use |
Moderate if supported by new clinical data |
| Device or packaging |
Moderate |
| Manufacturing process |
Moderate, but enforcement may be difficult |
| Data exclusivity |
Potentially valuable for a new indication or product |
What is the market outlook for crotamiton?
Public financial disclosures generally do not report crotamiton revenue as a separate line item. The market is fragmented across regional brands, generic manufacturers, wholesalers, pharmacy products, and institutional procurement. A defensible standalone global revenue figure cannot be established from public company filings.
The market outlook is therefore best assessed by demand drivers rather than by a single reported market-size number.
Market drivers
Crotamiton demand is supported by:
- Persistent scabies incidence.
- Institutional outbreaks in nursing homes, prisons, shelters, and crowded housing.
- Continued use for pruritus.
- Low manufacturing complexity.
- Regional availability where first-line products are constrained.
- Prescriber familiarity.
Market constraints
Demand is limited by:
- Stronger guideline preference for permethrin and ivermectin.
- Low product differentiation.
- Generic price competition.
- Limited clinical-trial investment.
- Uncertain reimbursement in some markets.
- Supply and distribution variability.
- Lack of a major new indication.
Five-year commercial projection
The base-case outlook is a mature, low-growth market. Volume may remain stable or grow modestly in regions with persistent scabies burden, while revenue may decline where price competition intensifies.
| Scenario |
Revenue direction through 2029-2030 |
Main assumptions |
| Downside |
Decline of 3% to 6% annually |
Generic price erosion, substitution by permethrin and ivermectin |
| Base case |
Flat to 3% annual growth |
Stable disease burden and continued regional use |
| Upside |
4% to 7% annual growth |
Supply shortages for alternatives, new formulation, or expanded institutional use |
These are scenario ranges, not reported consensus forecasts. The upside case requires a differentiated product or a favorable supply event. Conventional crotamiton cream and lotion alone are unlikely to produce high-single-digit sustained growth in developed markets.
What licensing deals involve crotamiton?
No major recent licensing transaction centered on crotamiton is broadly visible among the leading pharmaceutical business-development disclosures. Licensing economics are limited because the legacy product has low barriers to entry and generally modest revenue per unit.
A commercially meaningful deal would more likely involve:
- A novel crotamiton delivery system.
- A combination product.
- Rights in a territory with limited scabies-treatment access.
- A private-label or contract-manufacturing agreement.
- Institutional supply rights.
- A branded dermatology portfolio acquisition.
For a standard generic product, distribution and supply agreements are more commercially relevant than conventional innovation licensing.
What manufacturing and intellectual-property barriers exist?
Manufacturing barriers are moderate but manageable. Crotamiton is a small-molecule topical active, so production does not require biologic cell culture, sterile fill-finish, or complex device integration. The principal technical requirements are product uniformity, physical stability, preservative performance, microbial quality, packaging compatibility, and consistent skin feel.
Manufacturing risk areas
- Raw-material sourcing and supplier qualification.
- Batch-to-batch assay consistency.
- Emulsion stability.
- Viscosity and spreadability.
- Preservative efficacy.
- Tube or bottle compatibility.
- Stability under temperature excursions.
- Scale-up reproducibility.
- Regulatory documentation for excipients and impurities.
The manufacturing barrier is lower than for biologics and many modern dermatology products. The strongest defensible position would likely come from reliable supply, efficient cost structure, and a differentiated formulation rather than from legacy molecule patents.
What generic launch risks exist for crotamiton?
Generic launch risk is comparatively low for a conventional crotamiton product, but commercial success is not assured. A new entrant must address regulatory filing requirements, formulation similarity, bioequivalence expectations where applicable, manufacturing economics, and pharmacy channel access.
Generic-entry risk matrix
| Risk |
Level |
Commercial effect |
| Active-ingredient patent barrier |
Low |
Limited delay risk |
| Formulation patent barrier |
Low for conventional products |
Product-specific review required |
| Regulatory complexity |
Low to moderate |
Depends on application pathway |
| Manufacturing complexity |
Low to moderate |
Scale and stability remain important |
| Market size |
Low |
Limits return on development investment |
| Price competition |
High |
Can compress margins rapidly |
| Supply disruption |
Moderate |
Can create temporary opportunity |
| Brand loyalty |
Low to moderate |
Relevant in retail channels |
The most plausible generic launch scenario is a low-cost cream or lotion entering a fragmented market and competing for formulary, wholesale, and retail distribution. The launch would have limited value unless the sponsor already has a dermatology sales infrastructure or a broader topical portfolio.
How does crotamiton compare with permethrin and ivermectin?
| Factor |
Crotamiton |
Permethrin |
Ivermectin |
| Route |
Topical |
Topical |
Oral |
| Role in scabies |
Alternative |
Common first-line option |
Important systemic option |
| Patent status |
Mature, expired legacy estate |
Mature generic market |
Mature generic market |
| Adherence |
Application-dependent |
Application-dependent |
Oral convenience |
| Use in outbreaks |
Possible |
Common |
Useful for mass-treatment strategies |
| Clinical differentiation |
Limited |
Strong guideline position |
Systemic exposure and convenience |
| Commercial opportunity |
Low |
Larger generic market |
Larger generic and institutional market |
| Innovation potential |
Formulation or combination |
Delivery and resistance management |
New dosing or combination approaches |
Crotamiton’s commercial position is more defensive than growth-oriented. It can retain niche demand, but it lacks the clinical and economic advantages that drive large modern dermatology franchises.
Key Takeaways
- Crotamiton is a mature 10% topical scabicide and antipruritic.
- No substantial active Phase 2 or Phase 3 development program is publicly evident.
- Permethrin and ivermectin are stronger competitive standards in scabies treatment.
- The active ingredient and conventional topical use have no meaningful remaining exclusivity.
- Orange Book and Paragraph IV risk is limited for standard crotamiton products.
- No major current patent litigation or licensing campaign is associated with the legacy drug.
- Commercial demand is fragmented and generally low growth.
- A new formulation, combination, or adherence-focused delivery system would be required to create meaningful strategic upside.
- Manufacturing and regulatory barriers are manageable, but generic price competition is high.
- The base-case market outlook through 2029-2030 is flat to modest growth, with downside risk from substitution and price erosion.
FAQs
Is crotamiton still used to treat scabies?
Yes. Crotamiton remains available in certain markets and is used as an alternative topical scabicide, although permethrin and ivermectin have stronger positions in many treatment guidelines.
Is crotamiton stronger than permethrin?
Crotamiton is not generally regarded as clinically superior to permethrin for routine scabies treatment. Comparative outcomes depend on adherence, application, disease severity, and local treatment practices.
Does crotamiton have biosimilar competition?
No. Crotamiton is a small-molecule topical drug, so it faces generic competition rather than biosimilar competition.
Can a company obtain new patents on crotamiton?
Yes, but new protection would most plausibly cover a novel formulation, delivery system, combination, manufacturing process, or method of use. The old active ingredient itself cannot provide new composition-of-matter exclusivity.
Is crotamiton commercially attractive for a generic manufacturer?
It can be attractive as part of an existing dermatology or topical portfolio, particularly where supply is limited. As a standalone product, low market size, generic pricing, and limited differentiation reduce expected returns.
References
-
Centers for Disease Control and Prevention. (2024). Clinical care of scabies. https://www.cdc.gov/scabies/hcp/clinical-care/
-
DailyMed. (2024). Eurax: Crotamiton cream, 10% prescribing information. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/
-
U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs database. https://www.accessdata.fda.gov/scripts/cder/daf/
-
U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm
-
U.S. National Library of Medicine. (2024). Crotamiton. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/Crotamiton
